Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
IPO Year: 2020
Exchange: NYSE
Website: vicarioussurgical.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/4/2022 | $16.00 → $7.00 | Overweight → Neutral | Piper Sandler |
1/7/2022 | $16.00 | Outperform | Credit Suisse |
12/7/2021 | $15.00 | Outperform | Cowen & Co. |
11/5/2021 | $15.00 | Buy | Canaccord Genuity |
10/18/2021 | $15.00 | Buy | BTIG |
10/7/2021 | $16.00 | Overweight | Piper Sandler |
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2024. "Our team's strong execution throughout the year, continuing in the third quarter, has us on track to achieve our Version 1.0 System integration milestone within the next few weeks," said Adam Sachs, Co-Founder and Chief Executive Officer. "This sets the stage for us to complete our first clinical patient in less than a year, a criti
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the third quarter ended September 30, 2024 after the market closes on Tuesday, November 12, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 246564. A live and archived webcast of the event will be available at https://
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management is scheduled to present in a fireside chat on Friday, September 6, 2024 at 11:30 a.m. ET. About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's nove
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2024. "Our team's effective execution of our development plans during the first half of this year has positioned us well to achieve our V1.0 integration milestone this fall, as scheduled," said Adam Sachs, Co-Founder and Chief Executive Officer. "With the final refinements from our Spring lab now being integrated into the V1.0 system, we look fo
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed a strategic development agreement with the LSU Health New Orleans. LSU Health New Orleans is Louisiana's flagship and most comprehensive academic health sciences center. Known for the quality of its academic and training programs, the center educates the majority of Louisiana's health care professionals. LSU Health New Orleans partners with University Medical Center (UMC), which hosts the largest medical training center in Louisiana. At the heart of UMC's operations
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will report financial results for the second quarter ended June 30, 2024 after the market closes on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 997268. A live and archived webcast of the event will be available
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will effect a 1-for-30 reverse stock split of the Company's issued and outstanding Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share. The reverse stock split was approved by Vicarious Surgical's shareholders at the Company's annual shareholder meeting held on June 10, 2024, with the final ratio determined by the Company's Board of Directors within the ratio range authorized by shareholders. The reverse split is
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, April 29, 2024. "I'm proud to report a productive start to 2024 as we advance our mission to improve lives by transforming surgical robotics," said Adam Sachs, Co-Founder and Chief Executive Officer. "With the completion of our recent spring cadaver lab, we are now focused on further refining our V1.0 system ahead of final system integrati
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833 470 1428 for domestic callers or +1 404 975 4839 for international callers, using access code: 061323. A live and archived webcast of the event will be available at https
Version 1.0 Surgical System On Track for Cadaveric Testing this Spring Achieves 2023 Cash Burn Objective of $63.4 Million 2024 Cash Burn Guidance of $50 Million Reflects Prior Cost Reduction Initiatives Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, March 4, 2024. "We made meaningful progress transitioning our Beta 2 surgical system into our
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
10-Q - Vicarious Surgical Inc. (0001812173) (Filer)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
144 - Vicarious Surgical Inc. (0001812173) (Subject)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
S-8 - Vicarious Surgical Inc. (0001812173) (Filer)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
144 - Vicarious Surgical Inc. (0001812173) (Subject)
10-Q/A - Vicarious Surgical Inc. (0001812173) (Filer)
10-Q - Vicarious Surgical Inc. (0001812173) (Filer)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2024. "Our team's strong execution throughout the year, continuing in the third quarter, has us on track to achieve our Version 1.0 System integration milestone within the next few weeks," said Adam Sachs, Co-Founder and Chief Executive Officer. "This sets the stage for us to complete our first clinical patient in less than a year, a criti
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the third quarter ended September 30, 2024 after the market closes on Tuesday, November 12, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 246564. A live and archived webcast of the event will be available at https://
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2024. "Our team's effective execution of our development plans during the first half of this year has positioned us well to achieve our V1.0 integration milestone this fall, as scheduled," said Adam Sachs, Co-Founder and Chief Executive Officer. "With the final refinements from our Spring lab now being integrated into the V1.0 system, we look fo
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will report financial results for the second quarter ended June 30, 2024 after the market closes on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 997268. A live and archived webcast of the event will be available
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, April 29, 2024. "I'm proud to report a productive start to 2024 as we advance our mission to improve lives by transforming surgical robotics," said Adam Sachs, Co-Founder and Chief Executive Officer. "With the completion of our recent spring cadaver lab, we are now focused on further refining our V1.0 system ahead of final system integrati
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833 470 1428 for domestic callers or +1 404 975 4839 for international callers, using access code: 061323. A live and archived webcast of the event will be available at https
Version 1.0 Surgical System On Track for Cadaveric Testing this Spring Achieves 2023 Cash Burn Objective of $63.4 Million 2024 Cash Burn Guidance of $50 Million Reflects Prior Cost Reduction Initiatives Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, March 4, 2024. "We made meaningful progress transitioning our Beta 2 surgical system into our
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Monday, March 4, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833 470 1428 for domestic callers or +1 404 975 4839 for international callers, using access code: 608739. A live and archived webcast of the event will be a
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended September 30, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, November 13, 2023. "The third quarter brought several successes for our business, but also introduced new challenges as we focused on the build and integration of our Version 1.0 System," said Adam Sachs, Co-Founder and Chief Executive Officer. "While we were pleased with our ability to extend our cash runway
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the third quarter ended September 30, 2023, after the market closes on November 13, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 (404) 975 4839 for domestic callers or +1 (929) 526 1599 for international callers, and using access code: 083118. A live and archived webcast of the event will be available
Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously
Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00
Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00
Canaccord Genuity initiated coverage of Vicarious Surgical with a rating of Buy and set a new price target of $15.00
BTIG initiated coverage of Vicarious Surgical with a rating of Buy and set a new price target of $15.00
Piper Sandler initiated coverage of Vicarious Surgical with a rating of Overweight and set a new price target of $16.00
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a
Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari
Tech-Focused Venture Capitalists Dror Berman and Samir Kaul to Resign Beverly Huss Elected to Board of Directors Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the resignation of technology-focused venture capitalists Dror Berman and Samir Kaul from the Vicarious Surgical Board of Directors effective October 18, 2022. The Company also announced the appointment of Beverly Huss to the Vicarious Surgical Board of Directors, effective as of the same day. Ms. Huss will serve as a member of the Board's Audit Committee. "On behalf of the Board, I wou
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as the cost and efficiency of surgical procedures, today announced the appointment of John Mazzola as vice president of operations. In this new role, Mazzola will lead the strategic manufacturing plans for the Vicarious system as the company progresses development. Mazzola has more than 30 years of global operations and engineering management experience with leading companies in the medical device industry. Before joining Vicarious, Mazzola was a vice president of operations at Becton Dickinson Surgery. During his
Morgan Stanley analyst Patrick Wood maintains Vicarious Surgical (NYSE:RBOT) with a Equal-Weight and lowers the price target from $18 to $10.
Vicarious Surgical Inc (NASDAQ:RBOT) shares are trading lower by 20% to $0.29 during Tuesday’s session after the company announced a 1-for-30 reverse stock split of its Class A and Class B common stock. This decision, approved by shareholders at the annual meeting on June 10, is intended to increase the share price to meet the New York Stock Exchange’s minimum price requirement. The reverse stock split will take effect at 4:15 p.m. on June 12, and the Class A common stock will begin trading on a split-adjusted basis on June 13, under the ticker symbol “RBOT”. See Also: Apple’s AI Breakthroughs At WWDC 2024 Lead To Higher iPhone Sales Projections By Goldman Sachs RBOT Stock Predic
Shares of Contango Ore, Inc. (NYSE:CTGO) fell sharply during Tuesday's session after the company announced pricing of $15 million underwritten public offering. Contango Ore shares dipped 18.4% to $20.34 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Trio Petroleum Corp. (NYSE:TPET) shares jumped 88.2% to $0.4254 after the company completed its first two exploratory wells. Airship AI Holdings, Inc. (NASDAQ:AISP) shares climbed 32.5% to $4.1599. Airship AI announced a six-figure sole-source contract award within the Department of Justice for Acropolis Enterprise Video and Data Management Platform. Blue World Acquisition Corporation (NASDAQ
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
The Company anticipates that the 1-for-30 reverse stock split will be effective as of 4:15 p.m. on June 12, 2024 and the Company's Class A common stock will open for trading through the New York Stock Exchange on a post-split basis on June 13, 2024 under the Company's existing trading symbol "RBOT".
Gainers Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. Calidi Biotherapeutics (AME
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 103.2% to $1.0 during Thursday's pre-market session. The company's market cap stands at $23.7 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 30.67% to $0.41. The market value of their outstanding shares is at $4.1 million. P3 Health Partners (NASDAQ:PIII) stock increased by 25.51% to $0.63. The company's market cap stands at $75.3 million. Bicycle Therapeutics (NASDAQ:BCYC) stock increased by 12.04% to $24.0. The company's market cap stands at $913.7 million. Calliditas Therapeutics (NASDAQ:CALT) stock moved upwards by 11.42% to $24.19. The market value of their outstanding shares is at $649.1 million. The company's, Q1 ea
Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 days ago. Arcutis Biotherapeutics (NASDAQ:ARQT) stock increased by 18.92% to $9.67. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. MultiPlan (NYSE:MPLN) stock increased by 17.24% to $0.66. The market value of their outstanding shares is at $426.5 million. CASI Pharmaceuticals (NASDAQ:CASI) shares moved upwards by 15.45% to $3.66. The company's market cap stands at $49.0 million. As per the press release, Q1 earnings